DavidHoughMD

Summary

• David Hough, MD is currently serving as the Chief Medical Officer for Freedom Biosciences and a Senior Medical Advisor to Lykos Therapeutics. Prior to this role, Dr Hough was a Vice-President at Janssen (Johnson& Johnson) where he served for 17 years in several different leadership roles. His latest position was the SPRAVATO (esketamine) compound development team leader overseeing the development program through two severe mood disorder indications. He was responsible for all the medical, scientific, manufacturing, quality, preclinical, and commercial aspects of the program. Prior to that he was the schizophrenia disease area leader and the development team leader for paliperidone. He played a pivotal role in the development programs for oral INVEGA (paliperidone), INVEGA SUSTENNA/XEPLION (paliperidone palmitate) 1-month and 3-month formulations. Dave is a graduate of West Point and served for several years as a regular Army officer before attending medical school at the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland. After completing residency training in Psychiatry at Walter Reed Medical Center in Washington DC, he served for 10 years as an Army psychiatrist at two separate community hospitals and on faculty at a psychiatry residency program in Honolulu, Hawaii. He supervised numerous psychiatry residents and allied mental health professionals serving as head of outpatient clinics and behavioral health departments in different military hospitals.
  
  He completed a two-year research fellowship in Clinical Pharmacology jointly sponsored by USUHS and Walter Reed Army Institute of Research. He is board certified in both Adult and Geriatric Psychiatry and held an Adjunct Assistant Professor of Psychiatry position at USUHS for several years. He has authored numerous publications in peer reviewed journals, is a reviewer for several journals, and was an examiner for the American Board of Psychiatry and Neurology.